Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis.

Article Details

Citation

Copy to clipboard

Haugh IM, Preston AK, Kivelevitch DN, Menter AM

Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis.

Drug Des Devel Ther. 2018 Nov 12;12:3879-3883. doi: 10.2147/DDDT.S167149. eCollection 2018.

PubMed ID

30518998 [ View in PubMed

]

Abstract

Risankizumab, a fully human IgG monoclonal antibody inhibitor of IL-23, is a therapeutic agent currently in late stage development for use in the treatment of moderate-to-severe plaque psoriasis. It is a biologic agent similar to guselkumab and tildrakizumab which targets IL-23 specifically, and has been primarily developed for use in moderate-to-severe psoriasis. USA-based pharmaceutical company Abbvie submitted it for a Biologics License Application to the US Food and Drug Administration (FDA) in April 2018. Risankizumab is the result of a collaboration between the German company Boehringer Ingelheim and Abbvie, which together are leading the future development and commercialization of risankizumab globally. The results from Phase I to Phase III clinical trials of risankizumab show it is highly effective and its FDA-approval in 2018 is likely. In this article we provide an independent expert opinion on the efficacy and safety of risankizumab in psoriasis based on a full review of the literature.

DrugBank Data that Cites this Article

Drugs

Risankizumab

Drug Targets

Drug	Target	Kind	Organism	Pharmacological Action	Actions
Risankizumab	Interleukin-23 (Protein Group)	Protein group	Humans	Yes	Inhibitor	Details